English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use is an ongoing postmarketing study of ipragliflozin for long‐term use in Japanese patients with type 2 diabetes mellitus. A subgroup analysis of data from the study was carried out to investigate the impact of obesity on the efficacy and safety of ipragliflozin in this population.    Materials and Methods  Patients were divided into the following subgroups according to their body mass index ( BMI ): <22.0, 22.0 to <25.0, 25.0 to <30.0 and ≥30.0 kg/m 2 . Changes in bodyweight and glycemic parameters up to 3 months were evaluated, as well as adverse drug reactions ( ADR s) that occurred during ipragliflozin treatment.    Results  In the efficacy analysis set (8,633 patients), glycemic control and bodyweight statistically significantly improved from baseline to 3 months in all  BMI  subgroups (all  P  <   0.05). No strong correlations were identified between changes in bodyweight and changes in hemoglobin A1c, waist circumference or  BMI  in any of the subgroups. The incidence of adverse drug reactions was 6.29, 8.44, 11.18 and 11.74% in the <22.0, 22.0 to <25.0, 25.0 to <30.0 and ≥30.0 kg/m 2  groups, respectively ( P  =   0.001), in the safety analysis set ( n  = 11,053 patients).    Conclusions  In Japanese patients with type 2 diabetes mellitus, ipragliflozin improved glycemic control and reduced bodyweight, regardless of  BMI . Adverse drug reactions were more common in patients with higher  BMI  than in those with lower  BMI .

journal of diabetes investigation

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study